KMT2C and cancer: In most cancers, e.g., medulloblastoma [8], lung cancer [9], head and neck cancer [10], gastric cancer [11], squamous cell carcinoma [12], KMT2C mutations or low expression of KMT2C correlate with worse survival outcomes, whereas in tumors like breast cancer and pancreatic ductal adenocarcinoma, conflicting prognostic evidence exists [13–17].